



# SCYNEXIS, Inc.

July 11 2018

## Scynexis unveils favorable Phase 2b trials for yeast infection drug

A new antifungal drug developed by SCTNEXIS Inc (NASDAQ:SCYX) for the treatment of the yeast infection vulvovaginal candidiasis (VVC) has shown signs of superiority to standard treatments in a Phase2b clinical trial.

The news sent shares 10.3% higher to US\$1.82 in midday trade.

The Phase 2b study, known as DOVE, analyzed the effect of five different doses of SCY-078, which is taken orally, compared to fluconazole, the standard treatment for VVC.

The doses for the study, which enrolled 186 patients suffering from VVC, ranged from 600mg to 1800mg while the duration of the treatment was either one day or three. The lowest SCY-078 dose of 600mg, which was given as two doses of 300mg every 12 hours, showed the best clinical results.

**READ:** Maxim Group initiates SCYNEXIS with Buy rating on promise of antifungal drug SCY-078

After 10 days, 14 of 27 patients in the group taking 600mg of SCY-078 were cured of their yeast infections compared with 14 of 24 patients receiving fluconazole. Over longer periods, the results were even more favorable, with the rate of clinical cure in patients getting 600mg of SCY-078 jumping to 70% against the 50% cure rate of patients receiving fluconazole.

"The positive effect of oral SCY-078 seen in this study was achieved at greatly reduced doses and with improved tolerability compared to our previous VVC Phase 2a study," said David Angulo, chief medical officer of Scynexis. "The DOVE study accomplished its primary goal of identifying a well-tolerated oral dose regimen of SCY-078 with high clinical cure and mycological eradication rates."

The company is looking forward to a meeting with the US Food and Drug Administration to discuss the end of its Phase 2 trial and the start of registration for its Phase 3 trial.

The favorable results from the DOVE study follow the release of pre-clinical data that suggests SCY-078 has no negative impact on fertility, embryonic development or fetal development. The drug also works against the Candida species of fungal infections.

Keeping a Buy rating on the stock and a \$6 price target, Jason McCarthy, an analyst with Maxim Group, called the fresh data a "significant positive" for Scynexis that "should pave the way to Phase 3 studies later this year."

Currently, fluconazole is the sole oral option to treat VVC, which cracks the door open for the introduction of more antifungal therapies.

"With limited oral treatment options available for patients with VVC, and no approved products in recurrent VVC, the

**Price:** US\$1.38

**Market Cap:** US\$66.2M

### 1 Year Share Price Graph



### Share Information

**Code:** SCYX

**Listing:** NASDAQ

<b>52 week</b>	<b>High</b>	<b>Low</b>
	<b>2.14p</b>	<b>0.36p</b>

**Sector:** Health Care, Equipment & Services

**Website:** [www.scynexis.com](http://www.scynexis.com)

### Company Synopsis:

*We are committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies.*

### Author:

**Ellen Kelleher**

**+44(0)1202770386**

**action@proactiveinvestors.com**



results observed in this Phase 2b study reinforce SCY-078's potential to address the unmet needs in these patients," said Marco Taglietti, CEO of Scynexis.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

## No investment advice

Proactive Investors is a publisher and is not registered with or authorised by the Financial Conduct Authority (FCA). You understand and agree that no content published constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.



You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.